Influencer TOSSES Son Off Cliff, Then LAUGHS as Internet Slams Him
Read More
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore
Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers. CAR-T cell therapy is a form of immunotherapy that is currently only approved for use to treat blood cancers, such as certain types of lymphomas and multiple myeloma. As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, to drive the development of next-generation cell therapies. These technologies are already being investigated in Elpis' global clinical trials of EPC-002 and EPC-003, with the goal of expanding their translational relevance across multiple tumor types. Plans are also underway for Elpis to establish a laboratory space at NCCS and co-share its equipment to enable more integrated and efficient collaboration. "This partnership reflects our commitment to rapidly advancing innovative immunotherapies from discovery to clinical development through to regulatory review and, hopefully saving patients' lives," said Yan Chen, MD, PhD, Founder and CEO of Elpis Biopharmaceuticals. "By combining Elpis's proprietary technology with NCCS's clinical expertise, we look forward to accelerating the delivery of these potential groundbreaking new cancer therapies to patients in Singapore and beyond." NCCS will contribute its expertise in clinical research and access to clinical trial infrastructure to support the evaluation of novel cell therapy candidates. "The potential of using cell therapies for solid tumors is still being explored, and this collaboration will enable us to evaluate promising new technologies in a clinical context to address current unmet needs and improve patient outcomes," said Professor Lim Soon Thye, CEO of NCCS. "This is a key collaboration with NCCS' precision immunotherapy program. With our respective strengths and the shared goal of transforming clinical care through translational science, we look forward to offering clinical trials and developing novel cell therapies to better meet the needs of patients in Singapore and the region," added Professor Daniel Tan, Head, Division of Clinical Trials and Epidemiological Sciences and Senior Consultant, NCCS. The collaboration will support the development of bispecific armored CAR-T cell therapies for solid tumors, while Elpis's global leading mRNA display technology will support NCCS in the rapid discovery of human antibodies to novel targets and enable novel modalities to cell therapy and beyond. "The MOU represents an expansion of Elpis's living drug strategy and a key step toward enabling broader clinical translation of our cutting-edge cell therapy technologies," said Chee-Yong Lim, Co-Founder, Co-CEO & Chief Strategy Officer, Elpis Biopharmaceuticals. "Together, we are working to make living drugs a reality for patients with cancers that currently lack effective treatment options." About Elpis Biopharmaceuticals Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation cell therapies for the treatment of solid tumors. The company is advancing a pipeline of first- and best-in-class bispecific armored CAR-T therapies designed to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment. Its proprietary platforms—including a multi-mechanism armor technology, bispecific targeting antibodies, a cytokine cocktail-based cell manufacturing process, and a rapid mRNA display discovery engine—are integrated to deliver safer, more durable, and more effective therapeutic responses. Elpis's lead programs include EPC-003 for glioblastoma and EPC-002 for a broad range of solid tumors. Elpis Biopharmaceuticals is headquartered in Singapore and Boston, MA. For more information, visit Contact Tiberend Strategic Advisors, Inc. Jonathan Nugent (investors) +1-205-566-3026 jnugent@ Eric Reiss (media) ereiss@ View original content: SOURCE Elpis Biopharmaceuticals Sign in to access your portfolio
Yahoo
17 minutes ago
- Yahoo
Arseneault opens NBO with straight sets win over Royer
TORONTO — Wild-card entry Nicolas Arseneault of Richmond Hill, Ont., will be among those saluting Vasek Pospisil as the Canadian tennis veteran begins play in his final National Bank Open tournament on Sunday night. The 18-year-old Arseneault warmed up for the evening's featured match by knocking off 24-year-old qualifier Valentin Royer of France 6-3, 7-6 (4) in one hour, 45 minutes on the grandstand court at Sobeys Stadium. Royer had more winners (21-14) than Arseneault, but had more unforced errors (48-23). The Canadian had five aces, four double faults, a first serve percentage of 68, and won five of 11 break points. Royer had three aces, six double faults, a first serve percentage of 61 and only won four of nine break points. The 35-year-old Pospisil, from Vernon, B.C., will play Facundo Bagnis of Argentina on centre court in his opening round men's singles match. Pospisil has a career-high singles ranking of world No. 25, and No. 4 in doubles. Along with partner Jack Sock, he won the 2014 Wimbledon Championships and the 2015 Indian Wells Masters men's doubles titles. He also reached the quarterfinals in singles at the 2015 Wimbledon Championships. This report by The Canadian Press was first published July 27, 2025. The Canadian Press
Yahoo
17 minutes ago
- Yahoo
Beyoncé Closes Out Cowboy Carter Tour With Destiny's Child Reunion
The night marked the first time the trio have performed together since Coachella in 2018 Beyoncé closed out her Cowboy Carter world tour with a major surprise for fans: Michelle Williams and Kelly Rowland joined the superstar onstage for a Destiny's Child reunion. The crowd was ecstatic when Beyoncé, Rowland, and Williams appeared onstage and announced, 'Destiny's Child, b—ch!' The trio performed a medley of their hit songs including 'Lose My Breath' and 'Bootylicious' as well as 'Energy' from Beyoncé's 'Renaissance record. More from TheWrap Beyoncé Closes Out Cowboy Carter Tour With Destiny's Child Reunion | Video After 'Eddington:' 7 Offbeat Westerns to Watch Next Trump Demands Beyoncé Be Prosecuted Over Discredited Accusation She Was Paid $11 Million to Endorse Kamala Harris Hulk Hogan's Son Calls Him as 'the Most Incredible Person' and 'The Best Dad' in Emotional Tribute The performance was the first featuring the trio since Coachella in 2018. The singer was joined by Shaboozey for the duo's song 'Sweet Honey Buckiin' and by her husband Jay-Z for 'Crazy in Love.' The Los Angeles Times reported the concert was attended by Gayle King, Khloé Kardashian, Oprah Winfrey, Tyler Perry, Maya Rudolph and Kerry Washington. Beyoncé announced the 22-date tour in February. Shows began in Los Angeles in April and sprawled across the United States before the singer went overseas; she returned to the States for the final dates in Houston, Washington, D.C., Atlanta, and Las Vegas. The post Beyoncé Closes Out Cowboy Carter Tour With Destiny's Child Reunion | Video appeared first on TheWrap.
